Women with PCOS and secondary infertility are reporting pregnancies after starting GLP-1 medications, and TikTok videos on the topic have drawn millions of views. The accounts are anecdotal, and physicians caution that GLP-1 drugs are not fertility treatments. Separately, FDA guidance says…
Women are reporting pregnancies after taking GLP-1 weight-loss drugs, and the reports are spreading widely on social media. Videos on TikTok of women describing conception after starting a GLP-1 medication have drawn millions of views; the exact count has not been stated. The accounts are anecdotal, and experts are careful to draw a line: these drugs are not fertility treatments.
Two of those accounts were featured in interviews that aired on ABC News' Good Morning America on July 30, 2026. The article that accompanied the interviews was co-authored by Shafiq Najib and Isha Battu. Molly Orr, who has polycystic ovary syndrome PCOS , said she became pregnant roughly a year after starting a GLP-1 medication, despite having been told earlier that she would never conceive naturally. Areli Ruiz, who described secondary infertility after a previous birth, said she became pregnant three times in connection with intermittent use of a GLP-1 drug.
The timing matters because the reports arrive alongside a separate regulatory warning. The U.S. Food and Drug Administration FDA has warned that tirzepatide, sold as Mounjaro and Zepbound, may reduce the effectiveness of oral contraceptives. That warning is about contraception, not fertility, but it has placed GLP-1 drugs squarely in conversations about pregnancy, reproduction, and family planning.
Orr's account is the simpler of the two to frame. She has PCOS and said she started a GLP-1 medication after hearing it could improve PCOS symptoms. About a year later she became pregnant. "I really didn't have my hopes up, but when that test turned positive for like, I was ovulating, I was just floored. I remember getting so excited." The quote conveys the surprise, but it does not establish a cause. PCOS is a chronic condition, and many women with it conceive spontaneously after weight loss, after changes in medication, or without any intervention.
Ruiz described a longer and more specific pattern. She gave birth to her first daughter 17 years before the July 30, 2026 interview. She then had difficulty conceiving again, a situation commonly called secondary infertility. Her account links three pregnancies to intermittent GLP-1 use. She became pregnant 8 months after starting her first course, 6 months after a second course, and 1 month after a third course, for roughly 15 months of treatment-to-conception intervals. "I'm going to get on the GLP again ... got pregnant six months later, did it another time, got pregnant one month after again. So three GLP babies."
Ruiz also described the online community she found. "A lot of them went through infertility, the same exact journey and they have their GLP babies. It's crazy." The TikTok videos she and others posted are among the posts that have drawn millions of views. What the public accounts do not include is equally important: neither woman specified which GLP-1 medication she took, and neither provided a dose.
Self-selection is built into this kind of reporting. Women who conceive while taking a GLP-1 drug have a story to tell; women who take the same drug and do not conceive have no comparable event to post about. The millions of views on TikTok therefore measure the reach of a narrative, not the rate of an event. What is missing is the denominator: how many women of reproductive age have taken these drugs without becoming pregnant, and how that number compares with the number who conceived while on treatment. Without that comparison, a striking sequence of individual accounts cannot be converted into a claim about the drugs.
Set against the pregnancy reports is an FDA warning directed at tirzepatide, the drug sold as Mounjaro for diabetes and Zepbound for obesity. The agency warns that tirzepatide may reduce the effectiveness of oral contraceptives. For patients taking tirzepatide who rely on oral birth control, the FDA recommends using a backup contraceptive method or switching to a non-oral form for 4 weeks after starting treatment and for 4 weeks after every dose increase.
The warning does not say the drug improves fertility. It identifies a drug interaction. GLP-1 receptor agonists slow gastric emptying, and that slowing can change how rapidly or completely an oral medication is absorbed. For a drug like an oral contraceptive, where stable blood levels are central to efficacy, a change in absorption can matter clinically. That is also why the FDA's recommendation points to non-oral methods: a patch, ring, or implant is not absorbed through the stomach, while a backup barrier method covers the period when oral contraceptive levels may be low. The four-week windows around the start of therapy and around each dose increase reflect the periods when the drug's gastrointestinal effect is being introduced or intensified.
Tirzepatide is a dual agonist: it activates both the GLP-1 receptor and the receptor for glucose-dependent insulinotropic polypeptide GIP . Its slowing effect on gastric emptying is a known part of its pharmacology, and dose escalation, which is routine in this drug class, would be expected to change gastrointestinal motility again with each step up.
The warning and the anecdotes point in opposite directions, and holding both in view matters. The FDA action says that, in some patients, tirzepatide may make birth-control pills less effective, which, other things equal, could raise the chance of an unplanned pregnancy. The social media reports describe women who were trying to conceive and did so after starting a GLP-1 drug. One account is about contraceptive failure; the other is about a hoped-for conception. Neither is evidence that the drug treats infertility, and neither resolves how the drug might influence a woman's cycle.
GLP-1 receptor agonists are based on glucagon-like peptide-1, a gut hormone released after meals. The drugs amplify that signal. They increase glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and act on appetite centers in the brain to reduce food intake. The downstream effect in many patients is weight loss and improved insulin sensitivity. Those effects point to a plausible pathway to ovulation.
Reproduction is metabolically expensive, and the brain tunes fertility to fuel availability. A network of hypothalamic neurons, including kisspeptin neurons, links metabolic signals to the gonadotropin-releasing hormone GnRH pulse generator that drives the ovarian cycle. Chronic energy deficit suppresses that signal; sustained weight loss in an overweight or insulin-resistant woman can restore it. In PCOS, insulin resistance is thought to amplify ovarian androgen production, and lowering insulin can reduce that drive. Because even modest weight loss restores ovulation in some women with PCOS, a medication that produces sustained weight loss may indirectly restore regular cycles. That is the most straightforward way to understand Orr's report, though her case cannot separate the drug's metabolic effects from the weight loss they caused.
Secondary infertility is more varied. It may be ovulatory, tubal, uterine, or related to male factors. In Ruiz's case, the underlying cause was not described. Dr. Katherine Saunders, a physician interviewed for the July 30, 2026 segment, said GLP-1 medications are not fertility treatments but may improve fertility in women with insulin resistance by treating metabolic dysregulation, and that the effect would depend on a patient's individual medical condition. She put the clinical point directly: "It's not that these medications are fertility medications per se."
The open mechanistic question is which pathway, if any, explains the anecdotal reports. The candidates are weight loss, improved insulin resistance, and direct effects of the peptides on reproductive physiology. GLP-1 receptors are expressed in the brain, including hypothalamic regions close to the circuits that regulate appetite and reproduction, so a direct neural effect is not out of the question. Tirzepatide complicates the picture further because it adds the GIP axis, whose role in reproductive physiology is comparatively unstudied. The human data reported so far cannot separate any of these possibilities, and no controlled study has done so.
Peptide Atlas records for tirzepatide give a sense of the evidence base. The registry lists 252 registered clinical trials on file. The phase breakdown includes 5 Phase 2 trials, 2 Phase 4 trials, and 1 Phase 3 trial; 10 trials are listed as recruiting. The notable trials on file are listed below.
The list spans metabolic disease, addiction psychiatry, cardiac electrophysiology, and skeletal muscle biology. None of the notable trials has a fertility or pregnancy endpoint. That absence is not a criticism of the program; fertility was never the question these trials were built to answer. It does mean the anecdotes are arriving from outside the registered evidence base. Clinical trials of this class routinely do not enroll pregnant women, so the randomized program, as recorded, would not generate fetal-exposure data either. Any systematic answer about pregnancy will have to come from new studies or from pharmacovigilance reporting, not from the trials currently on file.
The published literature is similarly weighted toward metabolic outcomes. Peptide Atlas indexes 188 PubMed papers for tirzepatide. Recent literature includes a multicenter propensity-matched real-world study of tirzepatide versus SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease PMID 42397506, Hepatol Int, July 3, 2026 ; a case report of starvation-type euglycemic ketoacidosis after unsupervised tirzepatide use in a non-obese, non-diabetic woman PMID 42381258, Am J Case Rep, July 1, 2026 ; a review of tirzepatide as a multi-organ integrator in metabolic diseases PMID 42387035, Endocrine, July 1, 2026 ; a retrospective cohort study of tirzepatide in people with type 1 diabetes and overweight or obesity PMID 42387290, Diabetes Obes Metab, July 1, 2026 ; and a real-world comparative effectiveness study of tirzepatide and semaglutide for obesity PMID 42383938, Mayo Clin Proc, June 30, 2026 . The type 1 diabetes cohort is the one closest to the fertility question because it reports improved metabolic outcomes, the same pathway experts invoke to explain the anecdotal pregnancies; but it reports no conception rates, which is exactly the gap that matters. None of these papers is a fertility study. Peptide Atlas maintains a reference page for this data at https://peptideatlas.co/peptides/tirzepatide.
For clinicians, the takeaway is not that GLP-1 drugs cause pregnancy. It is that reproductive-age women taking these drugs need explicit counseling. For a woman with PCOS and insulin resistance, drug-induced weight loss may restore ovulation even though the prescription was written for diabetes or obesity. For a woman…
Peptides referenced: Semaglutide, Tirzepatide, Kisspeptin, Gonadorelin, Glucagon, Kisspeptin-10, GLP-1.
Related reading: GLP-1 Weight-Loss Drugs for $50 at Publix, CVS, Walmart, GLP-1 Microdosing Multisystem Benefits Reviewed in Cureus, Indiana Medicaid to cover GLP-1 obesity drugs via federal program, Enel Reports 3% Rise in H1 Core Earnings Despite Hit to Italian Hydro.